Skip to main content
. 2024 Sep 16;32(4):101342. doi: 10.1016/j.omtm.2024.101342

Figure 2.

Figure 2

Administration of AAV9-aGRIK2 decreases GluK2 protein expression in hippocampal neurons in vivo

(A) Schematic showing the two hippocampal injection sites for diluent, AAV9-control (5.0E+9 gc/hippocampus), or AAV9-aGRIK (at different doses) (orange); the corresponding in situ hybridization for miR1, at the sites of injection, is on the right. (B) Quantification of the vector genome copies in the hippocampus. (C) Quantification of miR1 in the hippocampus. (D) Quantification of miR2 in the hippocampus. (E) Correlation between vector copies and miRNA expression. (F) GluK2 protein expression up to 6 months after administration of AAV9-aGRIK2 or diluent in pilocarpine-treated epileptic mice. ∗∗p < 0.01, ∗∗∗∗p < 0.0001 one-way ANOVA, followed by Dunnett’s multiple comparison. Data are reported as mean ± SEM.